Introduction: An uncommon therapeutic entity is mucormycosis and immunocompromised patients are often affected by this infection. This fungus is under the order of the Mucorales. The Rhizopus genus is the most common causative organism related to mucormycosis. It is an acute disorder and there is a poor prognosis. Objective: To study the experiences of mucormycosis treatment at our tertiary care teaching hospital over the last three years in the head and neck area. Materials and Methods: A retrospective research involved 8 patients diagnosed with mucormycosis of the head and neck over 3 years between January 2019 and February 2021. Results: There are 5male and 3 female patients, aged between 29 to 65 years. Out of 8 patients, 4 were diabetic and the rests were with haematological disorders. There were 5 sinonasal mucormycosis and 3 non-sinonasal involvement. Diagnoses were established by histopathological study. In this study, two patients faced cerebral involvement. Conclusion: The early diagnosis and recovery from this infection are enhanced by early diagnosis with a tissue biopsy, local management of the disease by urgent surgical debridement and adequate systemic antifungal treatment. Mucormycosis therapy includes antifungal agents such as Amphotericin B and broad surgical debridement. Early diagnosis and care are also required for patients to survive.